Preliminary report of tolvaptan treatment in Japanese patients with heart failure.

While diuretic drugs are commonly used in patients with congestive heart failure, the efficacy of their long-term use still remains controversial. Recently, a new class of diuretics, vasopressin receptor 2 antagonists, has been launched, and tolvaptan is one such drug. We describe our initial experience with this novel agent. Tolvaptan is potentially useful for treatment of heart failure patients with fluid overload who are refractory to conventional diuretic therapies.

[1]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[2]  M. Kawana,et al.  Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. , 2010, American heart journal.

[3]  H. Shimokawa,et al.  Chronic heart failure in Japan: Implications of the CHART studies , 2008, Vascular health and risk management.

[4]  G. Fonarow,et al.  Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. , 2000, American heart journal.

[5]  Christopher M O'Connor,et al.  Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. , 2004, JAMA.

[6]  Eliot G. Peyster,et al.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Journal of the American College of Cardiology.

[7]  M. Hori,et al.  An Open-Label Study of Tolvaptan in the Heart Failure Patients With Volume Overload , 2010 .

[8]  K. Nakao,et al.  Inhibitory Effect of Natriuretic Peptides on Aldosterone Synthase Gene Expression in Cultured Neonatal Rat Cardiocytes , 2003, Circulation.

[9]  M. Drazner,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[10]  Y. Kagaya,et al.  Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[11]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[12]  M. Isobe,et al.  The Inhibitor of NF-κB Kinase Plays a Pivotal Role in the Development of Autoimmune Myocarditis in Rats , 2010 .

[13]  T Yamashita,et al.  OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[14]  G. Fonarow,et al.  Relation of loop diuretic dose to mortality in advanced heart failure. , 2006, The American journal of cardiology.

[15]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[16]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[17]  E. Espiner,et al.  Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure. , 1980, Clinical science.